[研究报告] 抗体发现市场规模预计将从 2022 年的 29.4 亿美元激增至 2030 年的 49.2 亿美元;预计 2022-2030 年期间市场复合年增长率为 6.7%。
分析师观点:
该报告包括当前抗体发现市场趋势及其在预测期内可预见的影响所带来的增长前景。全球慢性病患病率不断上升以及个性化医疗需求不断增长等因素推动了抗体药物发现市场的增长。老年人口罹患癌症、自身免疫性疾病和传染病等慢性病的风险很高,这反映了对生物制剂和药物治疗的需求。
此外,人们越来越关注开发更安全的抗体。例如,Humira 是一种人源化抗体,与传统的鼠抗体相比,它不太可能引起副作用。随着对药物安全性的日益重视,这种更安全的抗体预计将变得更加普遍。然而,严格的监管政策和对基因治疗和小分子药物等替代药物的需求激增限制了抗体发现市场的增长。此外,噬菌体展示、高通量筛选和生物信息学等技术进步正在促进新抗体的发现和开发。这使得药物开发过程更加高效、更具成本效益,并为市场创造了丰厚的增长机会。
市场概况:
生物制药行业高度专注于生物制剂,其扩张 导致对抗体研究服务的需求比以往更高。行业参与者和学术机构之间合作的增加促进了资源共享和加速抗体发现。以患者为中心的药物开发模式的转变,强调个性化医疗和患者偏好,推动了抗体发现市场的发展。
高通量筛选、噬菌体展示和下一代测序等持续的技术进步提高了抗体发现过程的效率和速度。政府组织和私营公司对研发活动的资金增加也刺激了抗体发现计划。单克隆抗体因其针对特定抗原的特异性和有效性而在治疗应用中越来越受欢迎,从而导致对抗体研究服务的需求增加。因此,对基于抗体的疗法的需求不断增长以及对外包的偏好可能会对未来几年的抗体发现市场预测产生重大影响。
定制此报告以满足您的需求
您可以免费定制任何报告,包括本报告的部分内容、国家级分析、Excel 数据包,以及为初创企业和大学提供优惠和折扣
- 获取此报告的关键市场趋势。这个免费样品将包括数据分析,从市场趋势到估计和预测。
市场驱动因素:
增加研发投入推动市场增长
抗体(包括单克隆抗体和多克隆抗体)在学术、研究和制药机构和组织中得到应用,其中它们用于与药物和生物标志物开发以及其他治疗和临床诊断产品开发相关的多项研发活动。中小型公司每年都专注于增加研发投资。2020 年 4 月,美国联邦政府根据《冠状病毒援助、救济和经济安全 (CARES) 法案》向生物医学高级研究与发展局 (BARDA) 拨款 35 亿美元,为疫苗、诊断、治疗和小分子活性药物成分 (API) 等的制造、生产和采购提供资金支持。例如,2022 年 9 月,Abzena(生物制剂和抗体-药物偶联物的领导者)宣布打算扩大其在剑桥的研发能力,以帮助快速发现抗体。此外,制药公司 Bio-Rad 提供 10,000 种抗体以及抗原、试剂和缓冲液,用于开发体外诊断测试。因此,制药公司不断增加对与抗体发现相关的研发活动的投资,以开发针对各种疾病的更好治疗方案,推动了抗体发现市场的增长。
节段分析:
抗体发现市场分析是通过考虑以下部分进行的:抗体类型、性质、服务和最终用户。
根据抗体类型,抗体发现市场细分为单克隆抗体、多克隆抗体和其他。单克隆抗体细分市场在 2022 年占据了最大的市场份额。此外,预计同一细分市场在 2022-2030 年期间的复合年增长率最高,为 6.9%。单克隆抗体 (mAb) 旨在与患病细胞特异性相互作用而不会损害健康细胞。癌症治疗是使用单克隆抗体的重要应用领域之一。这些是被广泛接受的生物制剂,预计在预测期内将为制药商带来数十亿美元的机会。此外,患者和医生对 mAb 治疗应用的认识越来越高。因此,预计在预测期内,重磅 mAb 作为各种适应症的有效治疗方法的批准将有利于抗体发现市场。Avastin、Herceptin、Remicade 和 Rituxan 等药物已被 FDA 批准用于治疗癌症、类风湿性关节炎、克罗恩病、溃疡性结肠炎等。
根据自然界,市场分为人类和人源化、嵌合和鼠类。人类和人源化部分在 2022 年占据了最大的抗体发现市场份额,预计同一部分在预测期内的复合年增长率会更高。人类和人源化抗体是通过将具有所需抗原结合特异性的非人类抗体的互补决定区 (CDR) 移植到另一种抗体的相应 CDR 中进行基因工程改造的,该抗体更主要来源于人类。这些抗体因其更高的特异性和稳定性以及更低的成本而获得了广泛的认可和普及。此外,人类和人源化抗体在临床研究中表现出了诱人的临床疗效。
根据服务,抗体发现市场分为噬菌体展示、杂交瘤、转基因动物、酵母展示和单细胞。噬菌体展示部分在 2022 年占据了市场份额的主导地位,预计同一部分在预测期内的复合年增长率最高,为 7.3%。噬菌体展示技术用于体外抗体选择。感染细菌的病毒主要用作表达抗体片段(蛋白质)的基因载体,这些抗体片段通常是病毒上存在的单链可变片段 (scFv) 或 Fab 片段。然后可以检查表达的抗体片段是否与特定的目标靶标结合。与结合剂识别过程相关的速度、简单性和成本效益是噬菌体展示技术的主要优势之一。
根据最终用户,抗体发现市场分为制药和生物技术公司、研究实验室和其他。制药和生物技术公司部门在 2022 年占据了最大的抗体发现市场份额,预计同一部门在 2022-2030 年期间的复合年增长率将达到 7.2%。制药和生物技术公司在抗体发现过程中占有很大一部分,因为它们有能力识别任何特定疾病的抗体并进行商业规模生产。药物发现和开发对高特异性抗体的需求不断增加;蛋白质组学和基因组学领域的研究不断增加;对抗体识别新靶点和检测方法的需求不断增加;以及癌症、艾滋病毒/艾滋病、免疫缺陷疾病和血液疾病等多个治疗领域的研发活动不断增加,这些都是推动制药和生物技术公司对抗体发现产品、解决方案和服务需求的关键因素。
区域分析:
抗体发现市场报告的范围包括北美、欧洲、亚太地区、中东和非洲以及南美和中美。2022 年北美市场价值 12.9 亿美元,预计到 2030 年将达到 22 亿美元;预计 2022-2030 年期间复合年增长率为 6.8%。北美市场分为美国、加拿大和墨西哥。该地区的市场增长取决于癌症患病率的增加、抗体研究行业的强大存在以及研发领域的技术进步。
根据美国癌症协会的数据,2020 年美国诊断出约 180 万例新癌症病例,约 606,520 例癌症相关死亡病例。这增加了对治疗性抗体的需求,从而推动了市场增长。预计亚太地区在 2022-2030 年期间的复合年增长率最高。亚太抗体发现市场分为中国、日本、印度、韩国、澳大利亚和亚太其他地区。中国在 2022 年占据最大的市场份额,预计印度将在市场上显示出显着的增长率。中国的生物制药行业正在经历巨大的转变,从以仿制药为中心的格局发展成为一个蓬勃发展的创新中心。此外,工业化的进步以及新药、高端医疗设备和技术的应用也促进了中国市场的增长。此外,越来越多的市场参与者将重点放在亚太国家,以进行地理扩张和其他增长战略,研究中心的数量不断增加,以及政府资金的显著增加,推动了亚太地区抗体发现市场的发展。
抗体发现市场区域洞察
Insight Partners 的分析师已详细解释了预测期内影响抗体发现市场的区域趋势和因素。本节还讨论了北美、欧洲、亚太地区、中东和非洲以及南美和中美洲的抗体发现市场细分和地理位置。
- 获取抗体发现市场的区域特定数据
抗体发现市场报告范围
报告属性 | 细节 |
---|---|
2022 年市场规模 | 29.4亿美元 |
2030 年的市场规模 | 49.2亿美元 |
全球复合年增长率(2022 - 2030 年) | 6.7% |
史料 | 2020-2021 |
预测期 | 2023-2030 |
涵盖的领域 | 按抗体类型
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
抗体发现市场参与者密度:了解其对业务动态的影响
抗体发现市场正在快速增长,这得益于最终用户需求的不断增长,这些需求源于消费者偏好的不断变化、技术进步以及对产品优势的认识不断提高等因素。随着需求的增加,企业正在扩大其产品范围,进行创新以满足消费者的需求,并利用新兴趋势,从而进一步推动市场增长。
市场参与者密度是指在特定市场或行业内运营的企业或公司的分布情况。它表明在给定市场空间中,相对于其规模或总市场价值,有多少竞争对手(市场参与者)存在。
在抗体发现市场运营的主要公司有:
- 创意生物实验室
- 埃沃泰克
- 保诺科技
- 布鲁克细胞分析
- 百奥赛特
免责声明:上面列出的公司没有按照任何特定顺序排列。
- 了解抗体发现市场的主要参与者概况
关键球员分析:
Creative Biolabs、Evotec、BioDuro-Sundia、Bruker Cellular Analysis、Biocytogen、Charles River Laboratories、Aragen Life Sciences Pvt. Ltd、Twist Bioscience、NanoCellect Biomedical 和 Sartorius AG 是抗体发现市场报告中介绍的主要参与者。
最新动态:
在抗体发现市场运营的公司采取并购、合作等战略举措。以下列出了一些最近的市场发展:
- 2024 年 1 月,百奥赛图制药有限公司推出了一个名为 RenBiologics 的新子品牌,代表公司的抗体发现业务部门。RenBiologics 业务预计将涵盖公司广泛的全人源抗体库的对外授权/共同开发,以及百奥赛图制药的全人源抗体/TCR 发现平台 RenMice 的授权。
- 2023 年 12 月,百奥赛图基因制药有限公司宣布与 Ona Therapeutics 达成一项抗体评估、选择权和许可协议,旨在设计针对晚期癌症类型的生物制药。根据协议条款,百奥赛图基因制药有限公司授予 Ona 评估其专有的 RenMice 衍生的针对特定肿瘤靶点的全人抗体的权利,并可选择独家许可选定的抗体,用于在双方商定的适应症和地区开发、制造和商业化抗体-药物偶联物 (ADC)。
- 2022 年 6 月,Evotec SE 宣布与强生旗下药物研发公司之一 Janssen Pharmaceutica NV 合作。根据合作,Evotec SE 将评估其 TargetAlloMod 平台,以发现具有新作用方式的同类首创治疗候选药物,而 Janssen Pharmaceutica NV 将促进这一进程。
- 2021 年 8 月,Sartorius AG 与麦克马斯特大学达成合作,以改进针对 COVID-19、癌症和遗传疾病等疾病的抗体和其他病毒治疗的生产工艺。与麦克马斯特大学的合作促成了具有影响力的研究,使重要的治疗方法得以更大规模地应用。
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Charles River Laboratories and Evotec are the top two companies that hold huge market shares in the antibody discovery market.
Global antibody discovery market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The North America regional market is expected to grow with a CAGR of 6.8% during 2022–2030. Market growth in this region is attributed to the increasing prevalence of cancer, the strong presence of the antibody research industry, and technological advancements in the R&D sector help in the market expansion. An upsurge in funding further enables the development of new technologies, pooling of resources and expertise across countries and organizations, and conducting research work into existing antibody treatments. This has led to a better understanding of the immune system, and the development of effective and targeted antibodies. Additionally, the increased funding allows scientists to conduct large-scale clinical trials that are mandatory to evaluate the effectiveness of a particular antibody. The Asia Pacific molecular spectroscopy market is expected to grow at the highest CAGR of 7.3% during 2022–2030. China is predicted to hold the largest share of the market in 2022, and India is expected to show a significant growth rate in the market. China is predicted to hold the largest market share in 2022, and India is expected to show a significant growth rate in the market. The biopharmaceutical industry in China is undergoing a tremendous shift, evolving from a generics-focused landscape to a thriving innovation hub. Additionally, progress in industrialization, and the application of novel drugs, high-end medical devices, and techniques contribute to the antibody discovery market growth in China. Further, the growing number of market players focusing on countries in Asia Pacific for their geographic expansion and other growth strategies, the rising count of research centers, and a notable increase in government funding fuel the antibody discovery market growth in Asia Pacific.
Antibody discovery, a nuanced endeavor, refers to the complicated process of discovering novel antibodies. This endeavor involves the search for antibodies that recognize and bind to specific targets, with applications extending to diagnostics and therapy. Antibody discovery methods such as phage display and hybridoma technology are widely used. Their use is essential to the search for antibodies that recognize and bind to specific targets, paving the way for applications in diagnostics and therapeutic interventions. The resulting outcome of this process plays a crucial role in developing novel drugs, vaccines, diagnostics, and various therapeutic modalities. By enabling researchers to produce antibodies tailored to recognize and target precise antigens, the scale of antibody discovery is of paramount importance.
Key factors that are driving the antibody discovery market are the increasing investments in research & development and the rising incidence of cancer.
The CAGR value of the antibody discovery market during the forecasted period of 2022-2030 is 6.7%.
The monoclonal antibodies segment held the largest share of the market in the global antibody discovery market and held the largest market share of 82.6% in 2022.
The phage display segment dominated the global antibody discovery market and held the largest market share of 35.8% in 2022.
The molecular spectroscopy market majorly consists of the players such Creative Biolabs, Evotec, BioDuro-Sundia, Bruker Cellular Analysis, Biocytogen, Charles River Laboratories, Aragen Life Sciences Pvt. Ltd, Twist Bioscience, NanoCellect Biomedical, and Sartorius AG.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies - Antibody Discovery Market
- Creative Biolabs
- Evotec
- BioDuro-Sundia
- Bruker Cellular Analysis
- Biocytogen
- Charles River Laboratories
- Aragen Life Sciences Pvt. Ltd
- Twist Bioscience
- NanoCellect Biomedical
- Sartorius AG
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.